YC-1: Dual sGC Activator & HIF-1α Inhibitor for Cancer & Hypoxia Research

Executive Summary: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a crystalline small molecule used widely in cancer and hypoxia signaling research. It acts as a soluble guanylyl cyclase (sGC) activator, elevating cGMP levels in vascular and platelet studies (APExBIO). YC-1 is a potent post-transcriptional inhibitor of hypoxia-inducible factor-1α (HIF-1α), blocking tumor survival pathways under hypoxic conditions. The compound inhibits HIF-1 transcriptional activity with an IC50 of 1.2 µM in vitro. YC-1 reduces tumor vascularization and expression of HIF-1α-dependent genes in animal models. It is highly soluble in DMSO and ethanol but insoluble in water, and is supplied at ≥98% purity for research use only.

Biological Rationale

Hypoxia-inducible factor-1α (HIF-1α) is a central regulator of the cellular response to low oxygen tension. Under hypoxia, HIF-1α accumulates and drives transcription of genes involved in angiogenesis, metabolism, and survival, contributing to tumor progression and metastasis (see this review). Soluble guanylyl cyclase (sGC) is another critical enzyme, catalyzing the conversion of GTP to cGMP, a second messenger involved in vasodilation, platelet function, and cellular signaling. Aberrant activation of these pathways is implicated in cancer, vascular disorders, and hypoxia-related diseases. YC-1 was developed to target both the oxygen-sensing (HIF-1α) and cGMP signaling pathways, providing researchers with a unique dual-action tool for dissecting tumor biology and hypoxia responses (compare optimized applications).

Mechanism of Action of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

YC-1 directly activates sGC independent of nitric oxide (NO), increasing intracellular cGMP concentrations in vascular smooth muscle cells and platelets (Elama et al., 2022). This leads to vasorelaxation and inhibition of platelet aggregation. Uniquely, YC-1 also suppresses HIF-1α protein accumulation through inhibition of its translation, not by altering mRNA levels, thereby reducing HIF-1 transcriptional activity. The IC50 for inhibition of hypoxia-induced HIF-1 is 1.2 µM in cell-based assays (APExBIO). In vivo, YC-1 treatment results in smaller, less vascularized tumors with suppressed expression of HIF-1α target genes such as VEGF. These dual mechanisms enable YC-1 to modulate both hypoxia and cGMP pathways, a property not shared by selective sGC activators or HIF-1α inhibitors alone (strategic mechanistic insights).

Evidence & Benchmarks

• YC-1 inhibits hypoxia-induced HIF-1 transcriptional activity with an IC50 of 1.2 µM at 37°C in standard cell culture conditions (APExBIO).
• In vitro, YC-1 activates sGC, leading to increased cGMP and inhibition of platelet aggregation (DOI:10.1016/j.saa.2021.120420).
• YC-1 reduces the size and vessel density of tumors in animal models of cancer at doses ranging from 10–50 mg/kg/day (see benchmarks).
• YC-1 is soluble at ≥30.4 mg/mL in DMSO and ≥16.2 mg/mL in ethanol, but insoluble in water, ensuring compatibility with standard laboratory solvents (APExBIO).
• Purity is consistently ≥98%, and solutions are recommended for prompt use; long-term storage is not advised (APExBIO).

Applications, Limits & Misconceptions

YC-1 (SKU B7641) is a validated tool for research in the following areas:

• Dissecting hypoxia signaling and HIF-1α-dependent transcriptional networks in cell and animal models (assay optimization guidance – this guide focuses on protocol integration, while the present article details molecular benchmarks).
• Studying the role of cGMP signaling in vascular biology, platelet function, and circulation disorders.
• Evaluating anti-angiogenic and anti-tumor effects in preclinical cancer models by inhibiting HIF-1α and reducing pro-angiogenic gene expression.
• Serving as a reference inhibitor in hypoxia, oxygen-sensing, and apoptosis research workflows.

YC-1 is not approved for diagnostic or therapeutic use in humans or animals (APExBIO).

Common Pitfalls or Misconceptions

• YC-1 is not selective for HIF-2α or other hypoxia-inducible factors; its primary effect is on HIF-1α.
• It does not activate sGC in the absence of proper cofactors or under denaturing conditions.
• YC-1 is insoluble in water and must be dissolved in DMSO or ethanol for use.
• Prolonged storage of YC-1 solutions leads to degradation; always use freshly prepared aliquots.
• Not suitable for in vivo studies requiring chronic dosing in aqueous vehicles.

Workflow Integration & Parameters

For inhibition of hypoxia-induced HIF-1 transcriptional activity, YC-1 is typically employed at concentrations of 0.5–10 µM in cell culture. For sGC activation studies, in vitro assays often use 1–100 µM, depending on cell type and endpoint. YC-1 is highly soluble in DMSO (≥30.4 mg/mL) and ethanol (≥16.2 mg/mL), allowing preparation of concentrated stock solutions. It is recommended to store solid YC-1 at room temperature, protected from light and moisture, and to use solutions immediately after preparation.

For in vivo studies, YC-1 dosing ranges from 10–50 mg/kg/day administered via appropriate vehicles (usually not aqueous). APExBIO’s YC-1 (SKU B7641) is supplied as a crystalline solid with ≥98% purity, supporting reproducibility in experimental design (product details).

Conclusion & Outlook

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a versatile research reagent that enables dual targeting of the hypoxia signaling and cGMP pathways. Its benchmarked activity as both a soluble guanylyl cyclase activator and HIF-1α inhibitor underpins its value for cancer, vascular, and apoptosis research. APExBIO offers high-purity YC-1 (SKU B7641), with validated solubility and activity profiles. Future research will likely expand its application to dissecting complex tumor microenvironments and developing hypoxia-modulating strategies. For more detailed mechanistic insights, see this strategic review, which YC-1’s dual action extends by providing distinct molecular benchmarks discussed herein.